Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
1. FDA authorized Phase 3 study for INT230-6 in metastatic soft tissue sarcoma. 2. Phase 2 INVINCIBLE-4 study for Triple Negative Breast Cancer shows promising advancements. 3. INT230-6 demonstrates enhanced median overall survival in clinical trials. 4. Discussion initiated for strategic collaborations regarding INT230-6. 5. Contracts in place with multiple leading hospitals for ongoing clinical studies.